摘要
“双打击”多发性骨髓瘤(MM)是一种近年来提出的基于细胞遗传学异常的特殊类型,旨在发现高危、极高危患者,目前尚无统一的界定标准,且缺乏标准的治疗方案。以往的回顾性分析显示,“双打击”MM的预后极差,复发及死亡风险很高。2019年,WALKER等针对“双打击”MM提出了明确的定义:TP53双等位基因失活或在ISSⅢ期的前提下CKS1B(1q21)扩增拷贝数≥4的患者。本文针对WALKER等提出的“双打击”MM定义,对其诊断、临床特征、预后及治疗等方面的最新研究进展作一综述。
Double-hit multiple myeloma(MM)is a special type of based on cytogenetic abnormalities to find out high risk,extremely high-risk patients having been proposed in recent years,there is no unified definition of standard,and lack of a standard treatment.Previous retrospective analysis shows that double-hit MM had very poor prognosis,and high risk of recurrence and death.In 2019,WALKER etc.put forward the definition of"double-hit"MM:bi-allelic TP53 inactivation or amplification(≥4 copies)of CKS1B(1q21)on the background of ISSⅢ.The article focus on WALKER etc.Putting forward the definition of"double-hit"MM for its diagnosis,clinical features,prognosis and treatment of the latest research progress.
作者
刘艳芳
王玉明
王艳琳
LIU Yanfang;WANG Yuming;WANG Yanlin(Department of Clinical Laboratory,the Second Affiliated Hospital of Kunming Medical University,Yunnan,Kunming,650000,China;Department of Clinical Laboratory,Yunnan Geriatric Hospital Clinical Laboratory,Yunnan,Kunming,650000,China)
出处
《当代医学》
2024年第1期191-194,共4页
Contemporary Medicine
